UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

AIDS (London), 2013-01, Vol.27 (1), p.81-85

2013

Volltextzugriff (PDF)

Newer Formulations of Risperidone: Remarks About Risperidone ISM

CNS drugs, 2020-10, Vol.34 (10), p.1087-1088

2020

Volltextzugriff (PDF)

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM

British journal of clinical pharmacology, 2024-09, Vol.90 (9), p.2256-2270

2024

Volltextzugriff (PDF)

Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]

Schizophrenia research, 2022-08, Vol.246, p.258-259

2022

Volltextzugriff (PDF)

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

Retrovirology, 2012-08, Vol.9 (1), p.68-68, Article 68

2012

Volltextzugriff (PDF)

Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy

Antimicrobial Agents and Chemotherapy, 2010-07, Vol.54 (7), p.3018-3020

2010

Volltextzugriff (PDF)

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Schizophrenia research, 2022-01, Vol.239, p.83-91

2022

Volltextzugriff (PDF)

Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4153-4158

2009

Volltextzugriff (PDF)

A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia

International clinical psychopharmacology, 2018-03, Vol.33 (2), p.79-87

2018

Volltextzugriff (PDF)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]

Drug design, development and therapy, 2022-06, Vol.16, p.1791-1792

2022

Volltextzugriff (PDF)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

Neuropsychiatric disease and treatment, 2023-01, Vol.19, p.219-232

2023

Volltextzugriff (PDF)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study

Drug design, development and therapy, 2021-01, Vol.15, p.4371-4382

2021

Volltextzugriff (PDF)

Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)

International clinical psychopharmacology, 2016-11, Vol.31 (6), p.323-331

2016

Volltextzugriff (PDF)

All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010

BMC infectious diseases, 2013-08, Vol.13 (1), p.382-382, Article 382

2013

Volltextzugriff (PDF)

Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class

Clinical microbiology and infection, 2012-11, Vol.18 (11), p.E485-E490

2012

Volltextzugriff (PDF)

Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection

Expert opinion on pharmacotherapy, 2012-05, Vol.13 (7), p.1007-1014

2012

Volltextzugriff (PDF)

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

Journal of antimicrobial chemotherapy, 2013-09, Vol.68 (9), p.1994-2002

2013

Volltextzugriff (PDF)

Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain

AIDS research and human retroviruses, 2011-06, Vol.27 (6), p.633-638

2011

Volltextzugriff (PDF)

Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

AIDS (London), 2010-01, Vol.24 (3), p.469-471

2010

Volltextzugriff (PDF)

Author's response: expert reviews: who are they for?

Expert opinion on pharmacotherapy, 2012-06, Vol.13 (8), p.1217-1218

2012

Volltextzugriff (PDF)

Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain

AIDS research and human retroviruses, 2009-10, Vol.25 (10), p.967-972

2009

Volltextzugriff (PDF)

HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines

AIDS reviews, 2009-01, Vol.11 (1), p.39-51

2009

Volltextzugriff (PDF)

Resistencia viral y barrera genética de atazanavir

Enfermedades infecciosas y microbiología clínica, 2008, Vol.26, p.28-33

2008

Volltextzugriff (PDF)

Viral resistance and genetic barrier of atazanavir

Enfermedades infecciosas y microbiologia clinica, 2008-12, Vol.26 Suppl 17, p.28

2008

Volltextzugriff (PDF)

Competencias docentes para la inclusión de alumnos con necesidades educativas especiales: una revisión sistemática

Revista complutense de educación, 2024-04, Vol.35 (2), p.393-405

2024

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(38)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Newer Formulations of Risperidone: Remarks About Risperidone ISM

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM

Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients

A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study

Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)

All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010

Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class

Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain

Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

Author's response: expert reviews: who are they for?

Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain

HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines

Resistencia viral y barrera genética de atazanavir

Viral resistance and genetic barrier of atazanavir

Competencias docentes para la inclusión de alumnos con necesidades educativas especiales: una revisión sistemática

Suchergebnisse filtern